SCHEMBL7148259

SCHEMBL7148259

O=C(NC(CO)CO)[C@@H]1C[C@@H](S)CN1C(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 1/20 0.54
POLB P06746 1/20 0.48
CTSL P07711 1/20 0.45
CTSK P43235 1/20 0.45
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
AGTR2 P50052 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KDM1A O60341 1/20 0.40
RCOR1 Q9UKL0 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.39
PREP P48147 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144595 0.84 POLB (0.48) CTRB1POLBCTSKKDM4ELMNA
SCHEMBL7150010 0.83 POLB (0.47) CTRB1POLBKMT2AKDM4ELMNA
SCHEMBL7146028 0.83 POLB (0.46) CTRB1POLBCTSLCTSK
SCHEMBL7150573 0.82 OPRM1 (0.54) CTRB1
SCHEMBL9120254 0.81 CTRB1 (0.41) CTRB1POLBTSHRL3MBTL1LMNA
SCHEMBL9121002 0.81 CTRB1 (0.41) CTRB1POLBTSHRL3MBTL1LMNA
SCHEMBL9041784 0.81 CYP3A4 (0.56) CTRB1POLBKMT2ATSHRKDM4E
SCHEMBL7147181 0.80 POLB (0.47) CTRB1POLBCTSLCTSKTSHR
SCHEMBL7147062 0.80 TSHR (0.49) CTRB1POLBKMT2ATSHRALDH1A1
SCHEMBL9241436 0.80 CTRB1 (0.40) CTRB1POLBCTSLCTSKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP CTRB1 283/4885POLB 1465/4885CTSL 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.